In our study, six patients were CD30-positive, three of whom were treated with BV (two patients with stage T3 tumors treated in the first-line setting, and another with a stage T2 tumor treated in the second-line setting), and the ORR was 100%. The gene discussed is TNFRSF8; the disease is neoplasm.